相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
Carmelo Carlo-Stella et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study
Mari Morita-Fujita et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Sezary syndrome of cutaneous T-cell lymphoma (CTCL)
Onder Alpdogan et al.
CHINESE CLINICAL ONCOLOGY (2019)
Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sezary Syndrome
Tomonori Oka et al.
FRONTIERS IN MEDICINE (2019)
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
Teresa Poggio et al.
CANCERS (2018)
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W. Flinn et al.
BLOOD (2018)
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Steven M. Horwitz et al.
BLOOD (2018)
Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma
Hiroo Katsuya et al.
BIOMARKER RESEARCH (2018)
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Francine Foss et al.
CANCER MEDICINE (2017)
The discovery and development of romidepsin for the treatment of T-cell lymphoma
Piotr Smolewski et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes
Hye Sun Park et al.
KOREAN JOURNAL OF RADIOLOGY (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities
Filiberto Cedeno-Laurent et al.
CLINICAL IMMUNOLOGY (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Bertrand Coiffier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
The Role of IL-32 in Cutaneous T-Cell Lymphoma
Hiraku Suga et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL- U)
Jun-ichi Kitagawa et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States
Abeer N. Abouyabis et al.
LEUKEMIA & LYMPHOMA (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Presence of circulating CCR10+T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides
Y Fujita et al.
CLINICAL CANCER RESEARCH (2006)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
分享论文
